Zimbabwe has turned down a significant US health deal worth $367m (£272m) spanning five years over Washington's insistence on sensitive biological samples.
This move came to light following a internal memorandum dated December was disclosed, which showed Head of State Emmerson Mnangagwa deemed the agreement was "unbalanced".
A government spokesman later explained that the US was requesting health data for research and profit but was unwilling to share the resulting advantages from any future medical innovations.
"We are forced to start the challenging and unfortunate process of scaling back our health assistance in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the US had provided over $1.9bn for health programmes to Zimbabwe over the last twenty years.
A doctors' association in Zimbabwe has appealed for further talks to find a agreement agreeable to both sides so the country's vital HIV treatment initiative can continue.
Wider Implications
This rejection follows a comparable situation in Kenya, where a high court blocked a related deal with the US following concerns were raised about the safety of Kenyans' health data.
After resuming office last year, US President Donald Trump has reduced overseas assistance and closed the US Agency for International Development (USAID).
USAID had administered aid for the American government, but Trump claimed its spending was "wasteful" and his administration was pursuing government-to-government agreements to boost openness and accountability.
According to reports, Sixteen African countries have so far agreed to similar agreements, constituting over $18.3bn of fresh investment.
Details of the Declined Deal
The money for Zimbabwe would have funded "combating HIV/Aids, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"We believe this partnership would have delivered extraordinary benefits for the people of Zimbabwe, particularly the 1.2 million men, women and children currently receiving HIV treatment through American-funded programmes," Tremont said.
However, government spokesperson Nick Mangwana said the arrangement was "unequal".
"Zimbabwe was being asked to surrender its biological resources and data for a long time, without any corresponding promise of access to any medical innovations – like new medicines or tests – that could be developed from that provided information," Mangwana explained.
"Effectively, our country would supply the raw materials for scientific discovery with no assurance that the resulting innovations would be accessible to our people if a future disease outbreak arise."
Sovereignty and International Frameworks
Mangwana further noted that the American exit from the global health body and its pursuit of bilateral deals were undermining systems already set up via the international organization.
Mangwana cited its Pathogen Access and Benefit Sharing scheme designed to deal with future pandemics.
"This mechanism is intended to guarantee that when a country provides its data, the benefits – including vaccines and treatments – are distributed fairly, not commercialised solely by those with the resources to create them."
Zimbabwe's reservations regarding the US deal "should not be misconstrued as anti-American sentiment," he added.
"We encourage continued discussions with our American counterparts on how future co-operation could be arranged in a manner that honours the sovereignty and dignity of both nations."
Health Experts Response
The Zimbabwe College of Public Health Physicians (ZCPHP) said it recognised the official position, but recommended that negotiations must proceed since much of the nation's HIV programmes were funded by foreign aid.
"If specific concerns arise, including those relating to information security or implementation frameworks, these can often be resolved via detailed discussion and mutually agreed protections," it said.
The situation highlights the ongoing challenges between receiving vital foreign assistance and safeguarding national sovereignty in an increasingly data-driven world.